Cargando…
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma
Despite advances in deciphering the molecular pathogenesis of diffuse large B-cell lymphoma (DLBCL), patients with relapsed/refractory disease, particularly those with adverse genetic features (e.g., mutated p53 or double hit lymphoma (DHL)) have very poor prognoses, and effective therapies are lack...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787470/ https://www.ncbi.nlm.nih.gov/pubmed/29416618 http://dx.doi.org/10.18632/oncotarget.20378 |
_version_ | 1783295936204636160 |
---|---|
author | Liu, Wei Chen, Juan Tamayo, Archito T. Ruan, Changgeng Li, Li Zhou, Shouhao Shen, Chan Young, Ken H. Westin, Jason Davis, Richard E. Hu, Shimin Medeiros, Leonard J. Ford, Richard J. Pham, Lan V. |
author_facet | Liu, Wei Chen, Juan Tamayo, Archito T. Ruan, Changgeng Li, Li Zhou, Shouhao Shen, Chan Young, Ken H. Westin, Jason Davis, Richard E. Hu, Shimin Medeiros, Leonard J. Ford, Richard J. Pham, Lan V. |
author_sort | Liu, Wei |
collection | PubMed |
description | Despite advances in deciphering the molecular pathogenesis of diffuse large B-cell lymphoma (DLBCL), patients with relapsed/refractory disease, particularly those with adverse genetic features (e.g., mutated p53 or double hit lymphoma (DHL)) have very poor prognoses, and effective therapies are lacking. In this study we examined the preclinical efficacy and associated biological effects of the first oral proteasome inhibitor, ixazomib, in DLBCL in vitro and in vivo models. We demonstrated that ixazomib exhibited anti-tumor activities in 28 representative DLBCL cell lines, 10 primary DLBCL samples, and a DHL xenotransplant mouse model, at clinically achievable drug concentrations. Ixazomib sensitivity in DLBCL cells is correlated with immunoproteasomal activity; stimulating lymphoma cells with interferon gamma induced immunoproteasome activity and sensitized these cells to ixazomib. In addition, we showed that ixazomib induces apoptosis and the DNA damage response pathway, through activation of the checkpoint kinase 2 (CHK2). Hence, pharmacological inhibition of CHK2 enhances the anti-tumor activity of ixazomib in DLBCL cells. Our results indicate that ixazomib is an effective proteasome inhibitor active in DLBCL, including DHL, and its combination with a CHK2 inhibitor offers a potentially more robust therapeutic regimen for treatment-resistant DLBCL. |
format | Online Article Text |
id | pubmed-5787470 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-57874702018-02-07 Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma Liu, Wei Chen, Juan Tamayo, Archito T. Ruan, Changgeng Li, Li Zhou, Shouhao Shen, Chan Young, Ken H. Westin, Jason Davis, Richard E. Hu, Shimin Medeiros, Leonard J. Ford, Richard J. Pham, Lan V. Oncotarget Research Paper Despite advances in deciphering the molecular pathogenesis of diffuse large B-cell lymphoma (DLBCL), patients with relapsed/refractory disease, particularly those with adverse genetic features (e.g., mutated p53 or double hit lymphoma (DHL)) have very poor prognoses, and effective therapies are lacking. In this study we examined the preclinical efficacy and associated biological effects of the first oral proteasome inhibitor, ixazomib, in DLBCL in vitro and in vivo models. We demonstrated that ixazomib exhibited anti-tumor activities in 28 representative DLBCL cell lines, 10 primary DLBCL samples, and a DHL xenotransplant mouse model, at clinically achievable drug concentrations. Ixazomib sensitivity in DLBCL cells is correlated with immunoproteasomal activity; stimulating lymphoma cells with interferon gamma induced immunoproteasome activity and sensitized these cells to ixazomib. In addition, we showed that ixazomib induces apoptosis and the DNA damage response pathway, through activation of the checkpoint kinase 2 (CHK2). Hence, pharmacological inhibition of CHK2 enhances the anti-tumor activity of ixazomib in DLBCL cells. Our results indicate that ixazomib is an effective proteasome inhibitor active in DLBCL, including DHL, and its combination with a CHK2 inhibitor offers a potentially more robust therapeutic regimen for treatment-resistant DLBCL. Impact Journals LLC 2017-08-21 /pmc/articles/PMC5787470/ /pubmed/29416618 http://dx.doi.org/10.18632/oncotarget.20378 Text en Copyright: © 2018 Liu et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Liu, Wei Chen, Juan Tamayo, Archito T. Ruan, Changgeng Li, Li Zhou, Shouhao Shen, Chan Young, Ken H. Westin, Jason Davis, Richard E. Hu, Shimin Medeiros, Leonard J. Ford, Richard J. Pham, Lan V. Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma |
title | Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma |
title_full | Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma |
title_fullStr | Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma |
title_full_unstemmed | Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma |
title_short | Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma |
title_sort | preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large b-cell lymphoma |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787470/ https://www.ncbi.nlm.nih.gov/pubmed/29416618 http://dx.doi.org/10.18632/oncotarget.20378 |
work_keys_str_mv | AT liuwei preclinicalefficacyandbiologicaleffectsoftheoralproteasomeinhibitorixazomibindiffuselargebcelllymphoma AT chenjuan preclinicalefficacyandbiologicaleffectsoftheoralproteasomeinhibitorixazomibindiffuselargebcelllymphoma AT tamayoarchitot preclinicalefficacyandbiologicaleffectsoftheoralproteasomeinhibitorixazomibindiffuselargebcelllymphoma AT ruanchanggeng preclinicalefficacyandbiologicaleffectsoftheoralproteasomeinhibitorixazomibindiffuselargebcelllymphoma AT lili preclinicalefficacyandbiologicaleffectsoftheoralproteasomeinhibitorixazomibindiffuselargebcelllymphoma AT zhoushouhao preclinicalefficacyandbiologicaleffectsoftheoralproteasomeinhibitorixazomibindiffuselargebcelllymphoma AT shenchan preclinicalefficacyandbiologicaleffectsoftheoralproteasomeinhibitorixazomibindiffuselargebcelllymphoma AT youngkenh preclinicalefficacyandbiologicaleffectsoftheoralproteasomeinhibitorixazomibindiffuselargebcelllymphoma AT westinjason preclinicalefficacyandbiologicaleffectsoftheoralproteasomeinhibitorixazomibindiffuselargebcelllymphoma AT davisricharde preclinicalefficacyandbiologicaleffectsoftheoralproteasomeinhibitorixazomibindiffuselargebcelllymphoma AT hushimin preclinicalefficacyandbiologicaleffectsoftheoralproteasomeinhibitorixazomibindiffuselargebcelllymphoma AT medeirosleonardj preclinicalefficacyandbiologicaleffectsoftheoralproteasomeinhibitorixazomibindiffuselargebcelllymphoma AT fordrichardj preclinicalefficacyandbiologicaleffectsoftheoralproteasomeinhibitorixazomibindiffuselargebcelllymphoma AT phamlanv preclinicalefficacyandbiologicaleffectsoftheoralproteasomeinhibitorixazomibindiffuselargebcelllymphoma |